PMID- 10068580
OWN - NLM
STAT- MEDLINE
DCOM- 19990421
LR  - 20211115
IS  - 0022-1899 (Print)
IS  - 0022-1899 (Linking)
VI  - 179
IP  - 4
DP  - 1999 Apr
TI  - A randomized trial of high- versus low-dose subcutaneous interleukin-2 outpatient 
      therapy for early human immunodeficiency virus type 1 infection.
PG  - 849-58
AB  - Forty-nine outpatients infected with human immunodeficiency virus with baseline 
      CD4 cell counts >/=500/mm3, who were on stable antiretroviral therapy, were 
      randomized to receive 5-day cycles of either low-dose (1.5 million IU [MIU] twice 
      a day) or high-dose (7.5 MIU twice a day) subcutaneous (sc) interleukin (IL)-2 
      every 4 or every 8 weeks. High-dose recipients experienced mean slopes of +116.1 
      cells/month and +2.7 %/month in CD4 cells and percents, respectively, whereas 
      low-dose recipients displayed mean slopes of +26.7 and +1.3% in the same 
      parameters. At month 6, high-dose recipients achieved a 94.8% increase in mean 
      CD4 cells over baseline compared with a 19.0% increase in low-dose recipients. 
      While high-dose recipients encountered more constitutional side effects, these 
      were generally not dose-limiting. High-dose scIL-2 therapy in outpatients with 
      early HIV-1 infection was well tolerated and induced dramatic, sustained rises in 
      CD4 cells.
FAU - Davey, R T Jr
AU  - Davey RT Jr
AD  - National Institute of Allergy and Infectious Diseases, National Institutes of 
      Health, Bethesda, MD 20892-1880, USA. rdavey@atlas. niaid.nih.gov
FAU - Chaitt, D G
AU  - Chaitt DG
FAU - Albert, J M
AU  - Albert JM
FAU - Piscitelli, S C
AU  - Piscitelli SC
FAU - Kovacs, J A
AU  - Kovacs JA
FAU - Walker, R E
AU  - Walker RE
FAU - Falloon, J
AU  - Falloon J
FAU - Polis, M A
AU  - Polis MA
FAU - Metcalf, J A
AU  - Metcalf JA
FAU - Masur, H
AU  - Masur H
FAU - Dewar, R
AU  - Dewar R
FAU - Baseler, M
AU  - Baseler M
FAU - Fyfe, G
AU  - Fyfe G
FAU - Giedlin, M A
AU  - Giedlin MA
FAU - Lane, H C
AU  - Lane HC
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Infect Dis
JT  - The Journal of infectious diseases
JID - 0413675
RN  - 0 (Interleukin-2)
SB  - IM
MH  - Acquired Immunodeficiency Syndrome/immunology/*therapy/virology
MH  - Adult
MH  - CD4 Lymphocyte Count
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Follow-Up Studies
MH  - *HIV-1
MH  - Humans
MH  - Injections, Subcutaneous
MH  - Interleukin-2/*administration & dosage/adverse effects/pharmacokinetics
MH  - Male
MH  - Middle Aged
EDAT- 1999/03/09 03:00
MHDA- 2000/03/21 09:00
CRDT- 1999/03/09 03:00
PHST- 1999/03/09 03:00 [pubmed]
PHST- 2000/03/21 09:00 [medline]
PHST- 1999/03/09 03:00 [entrez]
AID - JID980938 [pii]
AID - 10.1086/314678 [doi]
PST - ppublish
SO  - J Infect Dis. 1999 Apr;179(4):849-58. doi: 10.1086/314678.